Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
Phase II clinical study of irinotecan liposome (II)-based combination regimen as a treatment for irinotecan-resistant colorectal cancer.
Trial Details
- NCT ID
- NCT07044921
- Phase
- PHASE2
- Sponsor
- Chinese PLA General Hospital
- Status
- RECRUITING
- Cancer Type
- Colorectal Cancer
- Interventions
- Irinotecan Liposomes (II)+Cetuximab+Bevacizumabl
- Locations (sample)
- Beijing, China|39.9075,116.39723
Key Eligibility Criteria
- Patients agree and have signed an informed consent form and are willing and able to comply with scheduled visits, study treatment plan, laboratory …
- age: 18 years and older, male or female;
- patients with pathologically confirmed advanced colorectal cancer(excluding all other histological types);
- Patients with colorectal cancer who have received ≥ second-line systemic antitumor therapy (including chemotherapy with irinotecan regimen, targete…
For full eligibility, visit ClinicalTrials.gov.